nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—lung cancer—sarcoma	0.787	1	CtDrD
Pemetrexed—ATIC—pes—sarcoma	0.0104	0.117	CbGeAlD
Pemetrexed—ATIC—leg—sarcoma	0.00532	0.0595	CbGeAlD
Pemetrexed—ATIC—forelimb—sarcoma	0.00528	0.059	CbGeAlD
Pemetrexed—ATIC—hindlimb—sarcoma	0.00475	0.0531	CbGeAlD
Pemetrexed—ATIC—appendage—sarcoma	0.00408	0.0456	CbGeAlD
Pemetrexed—GART—myometrium—sarcoma	0.00207	0.0232	CbGeAlD
Pemetrexed—ATIC—mammary gland—sarcoma	0.00198	0.0222	CbGeAlD
Pemetrexed—GART—seminal vesicle—sarcoma	0.00187	0.0209	CbGeAlD
Pemetrexed—GART—hematopoietic system—sarcoma	0.00178	0.0199	CbGeAlD
Pemetrexed—SLC46A1—seminal vesicle—sarcoma	0.00152	0.017	CbGeAlD
Pemetrexed—SLC46A1—hematopoietic system—sarcoma	0.00144	0.0161	CbGeAlD
Pemetrexed—ATIC—embryo—sarcoma	0.00135	0.0151	CbGeAlD
Pemetrexed—GART—cardiac atrium—sarcoma	0.00135	0.0151	CbGeAlD
Pemetrexed—GART—lymphoid tissue—sarcoma	0.00125	0.014	CbGeAlD
Pemetrexed—ATIC—hematopoietic system—sarcoma	0.00121	0.0135	CbGeAlD
Pemetrexed—SLC29A1—mammary gland—sarcoma	0.00121	0.0135	CbGeAlD
Pemetrexed—GART—tendon—sarcoma	0.00118	0.0132	CbGeAlD
Pemetrexed—ATIC—connective tissue—sarcoma	0.00116	0.013	CbGeAlD
Pemetrexed—GART—bone marrow—sarcoma	0.00114	0.0127	CbGeAlD
Pemetrexed—ATIC—smooth muscle tissue—sarcoma	0.00106	0.0119	CbGeAlD
Pemetrexed—ATIC—skin of body—sarcoma	0.00105	0.0117	CbGeAlD
Pemetrexed—SLC46A1—lymphoid tissue—sarcoma	0.00102	0.0114	CbGeAlD
Pemetrexed—GART—testis—sarcoma	0.000975	0.0109	CbGeAlD
Pemetrexed—SLC46A1—tendon—sarcoma	0.000956	0.0107	CbGeAlD
Pemetrexed—DHFR—myometrium—sarcoma	0.000945	0.0106	CbGeAlD
Pemetrexed—GART—liver—sarcoma	0.000922	0.0103	CbGeAlD
Pemetrexed—ATIC—uterus—sarcoma	0.000913	0.0102	CbGeAlD
Pemetrexed—DHFR—embryo—sarcoma	0.000909	0.0102	CbGeAlD
Pemetrexed—SLC29A1—myometrium—sarcoma	0.000856	0.00956	CbGeAlD
Pemetrexed—DHFR—seminal vesicle—sarcoma	0.000854	0.00954	CbGeAlD
Pemetrexed—ATIC—lymphoid tissue—sarcoma	0.000851	0.00951	CbGeAlD
Pemetrexed—TYMS—hematopoietic system—sarcoma	0.00082	0.00916	CbGeAlD
Pemetrexed—DCK—myometrium—sarcoma	0.000818	0.00914	CbGeAlD
Pemetrexed—DHFR—hematopoietic system—sarcoma	0.000811	0.00907	CbGeAlD
Pemetrexed—SLC46A1—testis—sarcoma	0.000792	0.00885	CbGeAlD
Pemetrexed—TYMS—connective tissue—sarcoma	0.000789	0.00882	CbGeAlD
Pemetrexed—DCK—embryo—sarcoma	0.000787	0.00879	CbGeAlD
Pemetrexed—DHFR—connective tissue—sarcoma	0.000781	0.00873	CbGeAlD
Pemetrexed—SLC46A1—liver—sarcoma	0.000748	0.00836	CbGeAlD
Pemetrexed—DCK—seminal vesicle—sarcoma	0.000739	0.00825	CbGeAlD
Pemetrexed—SLC29A1—hematopoietic system—sarcoma	0.000735	0.00821	CbGeAlD
Pemetrexed—TYMS—Vinorelbine—Vincristine—sarcoma	0.000729	0.249	CbGdCrCtD
Pemetrexed—TYMS—Podofilox—Etoposide—sarcoma	0.000728	0.249	CbGdCrCtD
Pemetrexed—TYMS—smooth muscle tissue—sarcoma	0.000722	0.00807	CbGeAlD
Pemetrexed—TYMS—skin of body—sarcoma	0.000713	0.00796	CbGeAlD
Pemetrexed—SLC29A1—connective tissue—sarcoma	0.000708	0.00791	CbGeAlD
Pemetrexed—GART—lymph node—sarcoma	0.000707	0.0079	CbGeAlD
Pemetrexed—DCK—hematopoietic system—sarcoma	0.000702	0.00784	CbGeAlD
Pemetrexed—ATIC—testis—sarcoma	0.000662	0.0074	CbGeAlD
Pemetrexed—ATIC—liver—sarcoma	0.000626	0.007	CbGeAlD
Pemetrexed—DHFR—cardiac atrium—sarcoma	0.000616	0.00688	CbGeAlD
Pemetrexed—DHFR—uterus—sarcoma	0.000613	0.00685	CbGeAlD
Pemetrexed—TYMS—lymphoid tissue—sarcoma	0.000577	0.00645	CbGeAlD
Pemetrexed—SLC46A1—lymph node—sarcoma	0.000574	0.00641	CbGeAlD
Pemetrexed—DHFR—lymphoid tissue—sarcoma	0.000571	0.00638	CbGeAlD
Pemetrexed—SLC29A1—cardiac atrium—sarcoma	0.000558	0.00624	CbGeAlD
Pemetrexed—SLC29A1—uterus—sarcoma	0.000555	0.0062	CbGeAlD
Pemetrexed—TYMS—tendon—sarcoma	0.000542	0.00606	CbGeAlD
Pemetrexed—DHFR—tendon—sarcoma	0.000537	0.006	CbGeAlD
Pemetrexed—DCK—cardiac atrium—sarcoma	0.000533	0.00596	CbGeAlD
Pemetrexed—DCK—uterus—sarcoma	0.00053	0.00593	CbGeAlD
Pemetrexed—TYMS—bone marrow—sarcoma	0.000525	0.00587	CbGeAlD
Pemetrexed—DHFR—bone marrow—sarcoma	0.00052	0.00581	CbGeAlD
Pemetrexed—SLC29A1—lymphoid tissue—sarcoma	0.000517	0.00578	CbGeAlD
Pemetrexed—DCK—Doxorubicin—Epirubicin—sarcoma	0.000505	0.172	CbGdCrCtD
Pemetrexed—TYMS—Vinblastine—Vincristine—sarcoma	0.000501	0.171	CbGdCrCtD
Pemetrexed—DCK—lymphoid tissue—sarcoma	0.000494	0.00552	CbGeAlD
Pemetrexed—SLC29A1—tendon—sarcoma	0.000486	0.00544	CbGeAlD
Pemetrexed—ATIC—lymph node—sarcoma	0.00048	0.00536	CbGeAlD
Pemetrexed—SLC29A1—bone marrow—sarcoma	0.000471	0.00526	CbGeAlD
Pemetrexed—DCK—Epirubicin—Doxorubicin—sarcoma	0.000467	0.159	CbGdCrCtD
Pemetrexed—DCK—tendon—sarcoma	0.000465	0.00519	CbGeAlD
Pemetrexed—DCK—bone marrow—sarcoma	0.00045	0.00503	CbGeAlD
Pemetrexed—TYMS—testis—sarcoma	0.000449	0.00502	CbGeAlD
Pemetrexed—DHFR—testis—sarcoma	0.000445	0.00497	CbGeAlD
Pemetrexed—TYMS—liver—sarcoma	0.000425	0.00474	CbGeAlD
Pemetrexed—DHFR—liver—sarcoma	0.00042	0.0047	CbGeAlD
Pemetrexed—SLC29A1—testis—sarcoma	0.000403	0.0045	CbGeAlD
Pemetrexed—DCK—testis—sarcoma	0.000385	0.0043	CbGeAlD
Pemetrexed—SLC29A1—liver—sarcoma	0.000381	0.00425	CbGeAlD
Pemetrexed—DCK—liver—sarcoma	0.000364	0.00406	CbGeAlD
Pemetrexed—TYMS—lymph node—sarcoma	0.000326	0.00364	CbGeAlD
Pemetrexed—DHFR—lymph node—sarcoma	0.000322	0.0036	CbGeAlD
Pemetrexed—SLC29A1—lymph node—sarcoma	0.000292	0.00326	CbGeAlD
Pemetrexed—DCK—lymph node—sarcoma	0.000279	0.00312	CbGeAlD
Pemetrexed—Oedema—Vincristine—sarcoma	0.00019	0.00158	CcSEcCtD
Pemetrexed—Infection—Vincristine—sarcoma	0.000189	0.00157	CcSEcCtD
Pemetrexed—Dyspepsia—Thiotepa—sarcoma	0.000189	0.00157	CcSEcCtD
Pemetrexed—Nervous system disorder—Vincristine—sarcoma	0.000187	0.00155	CcSEcCtD
Pemetrexed—Decreased appetite—Thiotepa—sarcoma	0.000187	0.00155	CcSEcCtD
Pemetrexed—Thrombocytopenia—Vincristine—sarcoma	0.000186	0.00155	CcSEcCtD
Pemetrexed—Anaphylactic shock—Mitoxantrone—sarcoma	0.000185	0.00154	CcSEcCtD
Pemetrexed—Oedema—Mitoxantrone—sarcoma	0.000185	0.00154	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Thiotepa—sarcoma	0.000185	0.00154	CcSEcCtD
Pemetrexed—Decreased appetite—Dactinomycin—sarcoma	0.000185	0.00154	CcSEcCtD
Pemetrexed—Fatigue—Thiotepa—sarcoma	0.000185	0.00154	CcSEcCtD
Pemetrexed—Dysgeusia—Etoposide—sarcoma	0.000185	0.00154	CcSEcCtD
Pemetrexed—Infection—Mitoxantrone—sarcoma	0.000184	0.00153	CcSEcCtD
Pemetrexed—Fatigue—Dactinomycin—sarcoma	0.000184	0.00152	CcSEcCtD
Pemetrexed—Pain—Thiotepa—sarcoma	0.000184	0.00152	CcSEcCtD
Pemetrexed—Constipation—Thiotepa—sarcoma	0.000184	0.00152	CcSEcCtD
Pemetrexed—Shock—Mitoxantrone—sarcoma	0.000182	0.00151	CcSEcCtD
Pemetrexed—Pain—Dactinomycin—sarcoma	0.000182	0.00151	CcSEcCtD
Pemetrexed—Thrombocytopenia—Mitoxantrone—sarcoma	0.000182	0.00151	CcSEcCtD
Pemetrexed—Anorexia—Vincristine—sarcoma	0.000181	0.00151	CcSEcCtD
Pemetrexed—Skin disorder—Mitoxantrone—sarcoma	0.00018	0.00149	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Epirubicin—sarcoma	0.000179	0.00149	CcSEcCtD
Pemetrexed—Anorexia—Mitoxantrone—sarcoma	0.000177	0.00147	CcSEcCtD
Pemetrexed—Renal failure acute—Doxorubicin—sarcoma	0.000176	0.00146	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Thiotepa—sarcoma	0.000176	0.00146	CcSEcCtD
Pemetrexed—Anaemia—Etoposide—sarcoma	0.000175	0.00145	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Dactinomycin—sarcoma	0.000174	0.00145	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Vincristine—sarcoma	0.000173	0.00144	CcSEcCtD
Pemetrexed—Urticaria—Thiotepa—sarcoma	0.000171	0.00142	CcSEcCtD
Pemetrexed—Body temperature increased—Thiotepa—sarcoma	0.00017	0.00141	CcSEcCtD
Pemetrexed—Abdominal pain—Thiotepa—sarcoma	0.00017	0.00141	CcSEcCtD
Pemetrexed—Leukopenia—Etoposide—sarcoma	0.000169	0.0014	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000169	0.0014	CcSEcCtD
Pemetrexed—Abdominal pain—Dactinomycin—sarcoma	0.000168	0.0014	CcSEcCtD
Pemetrexed—Body temperature increased—Dactinomycin—sarcoma	0.000168	0.0014	CcSEcCtD
Pemetrexed—Mood swings—Epirubicin—sarcoma	0.000167	0.00138	CcSEcCtD
Pemetrexed—Loss of consciousness—Etoposide—sarcoma	0.000166	0.00138	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Doxorubicin—sarcoma	0.000166	0.00138	CcSEcCtD
Pemetrexed—Decreased appetite—Vincristine—sarcoma	0.000165	0.00137	CcSEcCtD
Pemetrexed—Dyspnoea—Mitoxantrone—sarcoma	0.000165	0.00137	CcSEcCtD
Pemetrexed—Blood creatinine increased—Epirubicin—sarcoma	0.000165	0.00137	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Vincristine—sarcoma	0.000164	0.00136	CcSEcCtD
Pemetrexed—Fatigue—Vincristine—sarcoma	0.000164	0.00136	CcSEcCtD
Pemetrexed—Dehydration—Epirubicin—sarcoma	0.000164	0.00136	CcSEcCtD
Pemetrexed—Dyspepsia—Mitoxantrone—sarcoma	0.000163	0.00135	CcSEcCtD
Pemetrexed—Hypertension—Etoposide—sarcoma	0.000163	0.00135	CcSEcCtD
Pemetrexed—Constipation—Vincristine—sarcoma	0.000163	0.00135	CcSEcCtD
Pemetrexed—Pain—Vincristine—sarcoma	0.000163	0.00135	CcSEcCtD
Pemetrexed—Decreased appetite—Mitoxantrone—sarcoma	0.000161	0.00134	CcSEcCtD
Pemetrexed—Chest pain—Etoposide—sarcoma	0.000161	0.00133	CcSEcCtD
Pemetrexed—Fatigue—Mitoxantrone—sarcoma	0.00016	0.00133	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00016	0.00133	CcSEcCtD
Pemetrexed—Pain—Mitoxantrone—sarcoma	0.000159	0.00132	CcSEcCtD
Pemetrexed—Constipation—Mitoxantrone—sarcoma	0.000159	0.00132	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.000158	0.00131	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.000158	0.00131	CcSEcCtD
Pemetrexed—Hypersensitivity—Thiotepa—sarcoma	0.000158	0.00131	CcSEcCtD
Pemetrexed—Hypersensitivity—Dactinomycin—sarcoma	0.000157	0.0013	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Vincristine—sarcoma	0.000156	0.00129	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Epirubicin—sarcoma	0.000155	0.00129	CcSEcCtD
Pemetrexed—Anaphylactic shock—Etoposide—sarcoma	0.000154	0.00128	CcSEcCtD
Pemetrexed—Mood swings—Doxorubicin—sarcoma	0.000154	0.00128	CcSEcCtD
Pemetrexed—Asthenia—Thiotepa—sarcoma	0.000154	0.00128	CcSEcCtD
Pemetrexed—Infection—Etoposide—sarcoma	0.000153	0.00127	CcSEcCtD
Pemetrexed—Asthenia—Dactinomycin—sarcoma	0.000153	0.00127	CcSEcCtD
Pemetrexed—Blood creatinine increased—Doxorubicin—sarcoma	0.000152	0.00127	CcSEcCtD
Pemetrexed—Dysphagia—Epirubicin—sarcoma	0.000152	0.00126	CcSEcCtD
Pemetrexed—Pruritus—Thiotepa—sarcoma	0.000152	0.00126	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000152	0.00126	CcSEcCtD
Pemetrexed—Dehydration—Doxorubicin—sarcoma	0.000151	0.00126	CcSEcCtD
Pemetrexed—Thrombocytopenia—Etoposide—sarcoma	0.000151	0.00125	CcSEcCtD
Pemetrexed—Abdominal pain—Vincristine—sarcoma	0.00015	0.00125	CcSEcCtD
Pemetrexed—Body temperature increased—Vincristine—sarcoma	0.00015	0.00125	CcSEcCtD
Pemetrexed—Skin disorder—Etoposide—sarcoma	0.00015	0.00124	CcSEcCtD
Pemetrexed—Pancreatitis—Epirubicin—sarcoma	0.000149	0.00124	CcSEcCtD
Pemetrexed—Angina pectoris—Epirubicin—sarcoma	0.000148	0.00123	CcSEcCtD
Pemetrexed—Urticaria—Mitoxantrone—sarcoma	0.000147	0.00122	CcSEcCtD
Pemetrexed—Anorexia—Etoposide—sarcoma	0.000147	0.00122	CcSEcCtD
Pemetrexed—Diarrhoea—Thiotepa—sarcoma	0.000147	0.00122	CcSEcCtD
Pemetrexed—Abdominal pain—Mitoxantrone—sarcoma	0.000147	0.00122	CcSEcCtD
Pemetrexed—Body temperature increased—Mitoxantrone—sarcoma	0.000147	0.00122	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000147	0.00122	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000147	0.00122	CcSEcCtD
Pemetrexed—Diarrhoea—Dactinomycin—sarcoma	0.000146	0.00121	CcSEcCtD
Pemetrexed—Pancytopenia—Epirubicin—sarcoma	0.000144	0.0012	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000144	0.00119	CcSEcCtD
Pemetrexed—Neutropenia—Epirubicin—sarcoma	0.000142	0.00118	CcSEcCtD
Pemetrexed—Dizziness—Thiotepa—sarcoma	0.000142	0.00118	CcSEcCtD
Pemetrexed—Dysphagia—Doxorubicin—sarcoma	0.000141	0.00117	CcSEcCtD
Pemetrexed—Hypersensitivity—Vincristine—sarcoma	0.00014	0.00116	CcSEcCtD
Pemetrexed—Pancreatitis—Doxorubicin—sarcoma	0.000138	0.00114	CcSEcCtD
Pemetrexed—Dyspnoea—Etoposide—sarcoma	0.000137	0.00114	CcSEcCtD
Pemetrexed—Angina pectoris—Doxorubicin—sarcoma	0.000137	0.00114	CcSEcCtD
Pemetrexed—Hypersensitivity—Mitoxantrone—sarcoma	0.000137	0.00113	CcSEcCtD
Pemetrexed—Asthenia—Vincristine—sarcoma	0.000137	0.00113	CcSEcCtD
Pemetrexed—Vomiting—Thiotepa—sarcoma	0.000136	0.00113	CcSEcCtD
Pemetrexed—Infestation—Epirubicin—sarcoma	0.000136	0.00112	CcSEcCtD
Pemetrexed—Infestation NOS—Epirubicin—sarcoma	0.000136	0.00112	CcSEcCtD
Pemetrexed—Vomiting—Dactinomycin—sarcoma	0.000135	0.00112	CcSEcCtD
Pemetrexed—Rash—Thiotepa—sarcoma	0.000135	0.00112	CcSEcCtD
Pemetrexed—Dermatitis—Thiotepa—sarcoma	0.000135	0.00112	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000134	0.00112	CcSEcCtD
Pemetrexed—Rash—Dactinomycin—sarcoma	0.000134	0.00111	CcSEcCtD
Pemetrexed—Decreased appetite—Etoposide—sarcoma	0.000134	0.00111	CcSEcCtD
Pemetrexed—Pancytopenia—Doxorubicin—sarcoma	0.000134	0.00111	CcSEcCtD
Pemetrexed—Renal failure—Epirubicin—sarcoma	0.000133	0.00111	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Etoposide—sarcoma	0.000133	0.0011	CcSEcCtD
Pemetrexed—Asthenia—Mitoxantrone—sarcoma	0.000133	0.0011	CcSEcCtD
Pemetrexed—Fatigue—Etoposide—sarcoma	0.000133	0.0011	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Epirubicin—sarcoma	0.000133	0.0011	CcSEcCtD
Pemetrexed—Stomatitis—Epirubicin—sarcoma	0.000132	0.0011	CcSEcCtD
Pemetrexed—Constipation—Etoposide—sarcoma	0.000132	0.00109	CcSEcCtD
Pemetrexed—Pain—Etoposide—sarcoma	0.000132	0.00109	CcSEcCtD
Pemetrexed—Conjunctivitis—Epirubicin—sarcoma	0.000132	0.00109	CcSEcCtD
Pemetrexed—Neutropenia—Doxorubicin—sarcoma	0.000132	0.00109	CcSEcCtD
Pemetrexed—Diarrhoea—Vincristine—sarcoma	0.00013	0.00108	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Epirubicin—sarcoma	0.000128	0.00106	CcSEcCtD
Pemetrexed—Nausea—Thiotepa—sarcoma	0.000128	0.00106	CcSEcCtD
Pemetrexed—Diarrhoea—Mitoxantrone—sarcoma	0.000127	0.00105	CcSEcCtD
Pemetrexed—Nausea—Dactinomycin—sarcoma	0.000127	0.00105	CcSEcCtD
Pemetrexed—Agranulocytosis—Epirubicin—sarcoma	0.000126	0.00105	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Etoposide—sarcoma	0.000126	0.00105	CcSEcCtD
Pemetrexed—Dizziness—Vincristine—sarcoma	0.000126	0.00104	CcSEcCtD
Pemetrexed—Infestation NOS—Doxorubicin—sarcoma	0.000125	0.00104	CcSEcCtD
Pemetrexed—Infestation—Doxorubicin—sarcoma	0.000125	0.00104	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000124	0.00103	CcSEcCtD
Pemetrexed—Renal failure—Doxorubicin—sarcoma	0.000123	0.00102	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Doxorubicin—sarcoma	0.000123	0.00102	CcSEcCtD
Pemetrexed—Urticaria—Etoposide—sarcoma	0.000123	0.00102	CcSEcCtD
Pemetrexed—Stomatitis—Doxorubicin—sarcoma	0.000122	0.00101	CcSEcCtD
Pemetrexed—Body temperature increased—Etoposide—sarcoma	0.000122	0.00101	CcSEcCtD
Pemetrexed—Abdominal pain—Etoposide—sarcoma	0.000122	0.00101	CcSEcCtD
Pemetrexed—Conjunctivitis—Doxorubicin—sarcoma	0.000122	0.00101	CcSEcCtD
Pemetrexed—Hepatitis—Epirubicin—sarcoma	0.000122	0.00101	CcSEcCtD
Pemetrexed—Vomiting—Vincristine—sarcoma	0.000121	0.001	CcSEcCtD
Pemetrexed—Pharyngitis—Epirubicin—sarcoma	0.000121	0.001	CcSEcCtD
Pemetrexed—Urinary tract disorder—Epirubicin—sarcoma	0.00012	0.000997	CcSEcCtD
Pemetrexed—Rash—Vincristine—sarcoma	0.00012	0.000996	CcSEcCtD
Pemetrexed—Dermatitis—Vincristine—sarcoma	0.00012	0.000995	CcSEcCtD
Pemetrexed—Urethral disorder—Epirubicin—sarcoma	0.000119	0.00099	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Doxorubicin—sarcoma	0.000119	0.000984	CcSEcCtD
Pemetrexed—Vomiting—Mitoxantrone—sarcoma	0.000118	0.000978	CcSEcCtD
Pemetrexed—Agranulocytosis—Doxorubicin—sarcoma	0.000117	0.000971	CcSEcCtD
Pemetrexed—Rash—Mitoxantrone—sarcoma	0.000117	0.00097	CcSEcCtD
Pemetrexed—Dermatitis—Mitoxantrone—sarcoma	0.000117	0.000969	CcSEcCtD
Pemetrexed—Erythema multiforme—Epirubicin—sarcoma	0.000115	0.000955	CcSEcCtD
Pemetrexed—Eye disorder—Epirubicin—sarcoma	0.000114	0.000944	CcSEcCtD
Pemetrexed—Hypersensitivity—Etoposide—sarcoma	0.000114	0.000943	CcSEcCtD
Pemetrexed—Nausea—Vincristine—sarcoma	0.000113	0.000938	CcSEcCtD
Pemetrexed—Hepatitis—Doxorubicin—sarcoma	0.000113	0.000934	CcSEcCtD
Pemetrexed—Pharyngitis—Doxorubicin—sarcoma	0.000112	0.000927	CcSEcCtD
Pemetrexed—Urinary tract disorder—Doxorubicin—sarcoma	0.000111	0.000923	CcSEcCtD
Pemetrexed—Asthenia—Etoposide—sarcoma	0.000111	0.000918	CcSEcCtD
Pemetrexed—Urethral disorder—Doxorubicin—sarcoma	0.00011	0.000916	CcSEcCtD
Pemetrexed—Nausea—Mitoxantrone—sarcoma	0.00011	0.000914	CcSEcCtD
Pemetrexed—Pruritus—Etoposide—sarcoma	0.000109	0.000905	CcSEcCtD
Pemetrexed—Arrhythmia—Epirubicin—sarcoma	0.000109	0.000902	CcSEcCtD
Pemetrexed—Alopecia—Epirubicin—sarcoma	0.000108	0.000892	CcSEcCtD
Pemetrexed—Erythema multiforme—Doxorubicin—sarcoma	0.000106	0.000883	CcSEcCtD
Pemetrexed—Malnutrition—Epirubicin—sarcoma	0.000106	0.000879	CcSEcCtD
Pemetrexed—Erythema—Epirubicin—sarcoma	0.000106	0.000879	CcSEcCtD
Pemetrexed—Diarrhoea—Etoposide—sarcoma	0.000106	0.000876	CcSEcCtD
Pemetrexed—Eye disorder—Doxorubicin—sarcoma	0.000105	0.000873	CcSEcCtD
Pemetrexed—Dysgeusia—Epirubicin—sarcoma	0.000104	0.000861	CcSEcCtD
Pemetrexed—Dizziness—Etoposide—sarcoma	0.000102	0.000846	CcSEcCtD
Pemetrexed—Arrhythmia—Doxorubicin—sarcoma	0.000101	0.000835	CcSEcCtD
Pemetrexed—Alopecia—Doxorubicin—sarcoma	9.95e-05	0.000826	CcSEcCtD
Pemetrexed—Vomiting—Etoposide—sarcoma	9.8e-05	0.000814	CcSEcCtD
Pemetrexed—Malnutrition—Doxorubicin—sarcoma	9.8e-05	0.000813	CcSEcCtD
Pemetrexed—Erythema—Doxorubicin—sarcoma	9.8e-05	0.000813	CcSEcCtD
Pemetrexed—Anaemia—Epirubicin—sarcoma	9.79e-05	0.000812	CcSEcCtD
Pemetrexed—Rash—Etoposide—sarcoma	9.72e-05	0.000807	CcSEcCtD
Pemetrexed—Dermatitis—Etoposide—sarcoma	9.71e-05	0.000806	CcSEcCtD
Pemetrexed—Dysgeusia—Doxorubicin—sarcoma	9.6e-05	0.000796	CcSEcCtD
Pemetrexed—Syncope—Epirubicin—sarcoma	9.5e-05	0.000788	CcSEcCtD
Pemetrexed—Leukopenia—Epirubicin—sarcoma	9.48e-05	0.000787	CcSEcCtD
Pemetrexed—Loss of consciousness—Epirubicin—sarcoma	9.31e-05	0.000773	CcSEcCtD
Pemetrexed—Nausea—Etoposide—sarcoma	9.16e-05	0.00076	CcSEcCtD
Pemetrexed—Hypertension—Epirubicin—sarcoma	9.14e-05	0.000759	CcSEcCtD
Pemetrexed—Anaemia—Doxorubicin—sarcoma	9.06e-05	0.000752	CcSEcCtD
Pemetrexed—Myalgia—Epirubicin—sarcoma	9.02e-05	0.000748	CcSEcCtD
Pemetrexed—Chest pain—Epirubicin—sarcoma	9.02e-05	0.000748	CcSEcCtD
Pemetrexed—Arthralgia—Epirubicin—sarcoma	9.02e-05	0.000748	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	8.95e-05	0.000743	CcSEcCtD
Pemetrexed—Syncope—Doxorubicin—sarcoma	8.79e-05	0.000729	CcSEcCtD
Pemetrexed—Leukopenia—Doxorubicin—sarcoma	8.77e-05	0.000728	CcSEcCtD
Pemetrexed—Oedema—Epirubicin—sarcoma	8.64e-05	0.000717	CcSEcCtD
Pemetrexed—Anaphylactic shock—Epirubicin—sarcoma	8.64e-05	0.000717	CcSEcCtD
Pemetrexed—Loss of consciousness—Doxorubicin—sarcoma	8.61e-05	0.000715	CcSEcCtD
Pemetrexed—Infection—Epirubicin—sarcoma	8.59e-05	0.000713	CcSEcCtD
Pemetrexed—Shock—Epirubicin—sarcoma	8.5e-05	0.000706	CcSEcCtD
Pemetrexed—Nervous system disorder—Epirubicin—sarcoma	8.48e-05	0.000703	CcSEcCtD
Pemetrexed—Thrombocytopenia—Epirubicin—sarcoma	8.46e-05	0.000702	CcSEcCtD
Pemetrexed—Hypertension—Doxorubicin—sarcoma	8.46e-05	0.000702	CcSEcCtD
Pemetrexed—Skin disorder—Epirubicin—sarcoma	8.4e-05	0.000697	CcSEcCtD
Pemetrexed—Chest pain—Doxorubicin—sarcoma	8.34e-05	0.000692	CcSEcCtD
Pemetrexed—Arthralgia—Doxorubicin—sarcoma	8.34e-05	0.000692	CcSEcCtD
Pemetrexed—Myalgia—Doxorubicin—sarcoma	8.34e-05	0.000692	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	8.29e-05	0.000688	CcSEcCtD
Pemetrexed—Anorexia—Epirubicin—sarcoma	8.24e-05	0.000684	CcSEcCtD
Pemetrexed—Oedema—Doxorubicin—sarcoma	8e-05	0.000664	CcSEcCtD
Pemetrexed—Anaphylactic shock—Doxorubicin—sarcoma	8e-05	0.000664	CcSEcCtD
Pemetrexed—Infection—Doxorubicin—sarcoma	7.95e-05	0.000659	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Epirubicin—sarcoma	7.88e-05	0.000654	CcSEcCtD
Pemetrexed—Shock—Doxorubicin—sarcoma	7.87e-05	0.000653	CcSEcCtD
Pemetrexed—Nervous system disorder—Doxorubicin—sarcoma	7.84e-05	0.000651	CcSEcCtD
Pemetrexed—Thrombocytopenia—Doxorubicin—sarcoma	7.83e-05	0.00065	CcSEcCtD
Pemetrexed—Skin disorder—Doxorubicin—sarcoma	7.77e-05	0.000645	CcSEcCtD
Pemetrexed—Dyspnoea—Epirubicin—sarcoma	7.71e-05	0.00064	CcSEcCtD
Pemetrexed—Anorexia—Doxorubicin—sarcoma	7.62e-05	0.000633	CcSEcCtD
Pemetrexed—Dyspepsia—Epirubicin—sarcoma	7.61e-05	0.000631	CcSEcCtD
Pemetrexed—Decreased appetite—Epirubicin—sarcoma	7.51e-05	0.000624	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Epirubicin—sarcoma	7.46e-05	0.000619	CcSEcCtD
Pemetrexed—Fatigue—Epirubicin—sarcoma	7.45e-05	0.000618	CcSEcCtD
Pemetrexed—Pain—Epirubicin—sarcoma	7.39e-05	0.000613	CcSEcCtD
Pemetrexed—Constipation—Epirubicin—sarcoma	7.39e-05	0.000613	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Doxorubicin—sarcoma	7.29e-05	0.000605	CcSEcCtD
Pemetrexed—Dyspnoea—Doxorubicin—sarcoma	7.13e-05	0.000592	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Epirubicin—sarcoma	7.07e-05	0.000587	CcSEcCtD
Pemetrexed—Dyspepsia—Doxorubicin—sarcoma	7.04e-05	0.000584	CcSEcCtD
Pemetrexed—Decreased appetite—Doxorubicin—sarcoma	6.95e-05	0.000577	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Doxorubicin—sarcoma	6.91e-05	0.000573	CcSEcCtD
Pemetrexed—Fatigue—Doxorubicin—sarcoma	6.9e-05	0.000572	CcSEcCtD
Pemetrexed—Urticaria—Epirubicin—sarcoma	6.87e-05	0.00057	CcSEcCtD
Pemetrexed—Pain—Doxorubicin—sarcoma	6.84e-05	0.000568	CcSEcCtD
Pemetrexed—Constipation—Doxorubicin—sarcoma	6.84e-05	0.000568	CcSEcCtD
Pemetrexed—Body temperature increased—Epirubicin—sarcoma	6.83e-05	0.000567	CcSEcCtD
Pemetrexed—Abdominal pain—Epirubicin—sarcoma	6.83e-05	0.000567	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Doxorubicin—sarcoma	6.54e-05	0.000543	CcSEcCtD
Pemetrexed—Hypersensitivity—Epirubicin—sarcoma	6.37e-05	0.000528	CcSEcCtD
Pemetrexed—Urticaria—Doxorubicin—sarcoma	6.35e-05	0.000527	CcSEcCtD
Pemetrexed—Abdominal pain—Doxorubicin—sarcoma	6.32e-05	0.000525	CcSEcCtD
Pemetrexed—Body temperature increased—Doxorubicin—sarcoma	6.32e-05	0.000525	CcSEcCtD
Pemetrexed—Asthenia—Epirubicin—sarcoma	6.2e-05	0.000515	CcSEcCtD
Pemetrexed—Pruritus—Epirubicin—sarcoma	6.12e-05	0.000508	CcSEcCtD
Pemetrexed—Diarrhoea—Epirubicin—sarcoma	5.91e-05	0.000491	CcSEcCtD
Pemetrexed—Hypersensitivity—Doxorubicin—sarcoma	5.89e-05	0.000489	CcSEcCtD
Pemetrexed—Asthenia—Doxorubicin—sarcoma	5.74e-05	0.000476	CcSEcCtD
Pemetrexed—Dizziness—Epirubicin—sarcoma	5.72e-05	0.000474	CcSEcCtD
Pemetrexed—Pruritus—Doxorubicin—sarcoma	5.66e-05	0.00047	CcSEcCtD
Pemetrexed—Vomiting—Epirubicin—sarcoma	5.5e-05	0.000456	CcSEcCtD
Pemetrexed—Diarrhoea—Doxorubicin—sarcoma	5.47e-05	0.000454	CcSEcCtD
Pemetrexed—Rash—Epirubicin—sarcoma	5.45e-05	0.000452	CcSEcCtD
Pemetrexed—Dermatitis—Epirubicin—sarcoma	5.45e-05	0.000452	CcSEcCtD
Pemetrexed—Dizziness—Doxorubicin—sarcoma	5.29e-05	0.000439	CcSEcCtD
Pemetrexed—Nausea—Epirubicin—sarcoma	5.13e-05	0.000426	CcSEcCtD
Pemetrexed—Vomiting—Doxorubicin—sarcoma	5.09e-05	0.000422	CcSEcCtD
Pemetrexed—Rash—Doxorubicin—sarcoma	5.04e-05	0.000418	CcSEcCtD
Pemetrexed—Dermatitis—Doxorubicin—sarcoma	5.04e-05	0.000418	CcSEcCtD
Pemetrexed—Nausea—Doxorubicin—sarcoma	4.75e-05	0.000394	CcSEcCtD
Pemetrexed—GART—Folate Metabolism—HBA1—sarcoma	2.02e-05	0.119	CbGpPWpGaD
Pemetrexed—SLC29A1—Fluoropyrimidine Activity—SMUG1—sarcoma	1.18e-05	0.0695	CbGpPWpGaD
Pemetrexed—SLC46A1—Folate Metabolism—HBA1—sarcoma	1.09e-05	0.0641	CbGpPWpGaD
Pemetrexed—DHFR—Fluoropyrimidine Activity—SMUG1—sarcoma	8e-06	0.047	CbGpPWpGaD
Pemetrexed—TYMS—Fluoropyrimidine Activity—SMUG1—sarcoma	6.98e-06	0.041	CbGpPWpGaD
Pemetrexed—GART—Folate Metabolism—IL2—sarcoma	6.56e-06	0.0386	CbGpPWpGaD
Pemetrexed—DHFR—Folate Metabolism—HBA1—sarcoma	5.85e-06	0.0344	CbGpPWpGaD
Pemetrexed—GART—Folate Metabolism—TP53—sarcoma	4.22e-06	0.0248	CbGpPWpGaD
Pemetrexed—SLC46A1—Folate Metabolism—IL2—sarcoma	3.54e-06	0.0208	CbGpPWpGaD
Pemetrexed—SLC29A1—Fluoropyrimidine Activity—TP53—sarcoma	3.14e-06	0.0185	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	2.45e-06	0.0144	CbGpPWpGaD
Pemetrexed—SLC46A1—Folate Metabolism—TP53—sarcoma	2.28e-06	0.0134	CbGpPWpGaD
Pemetrexed—DHFR—Fluoropyrimidine Activity—TP53—sarcoma	2.13e-06	0.0125	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	2.12e-06	0.0125	CbGpPWpGaD
Pemetrexed—DHFR—Folate Metabolism—IL2—sarcoma	1.9e-06	0.0112	CbGpPWpGaD
Pemetrexed—TYMS—Fluoropyrimidine Activity—TP53—sarcoma	1.85e-06	0.0109	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	1.85e-06	0.0109	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	1.71e-06	0.01	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—STAG1—sarcoma	1.64e-06	0.00963	CbGpPWpGaD
Pemetrexed—GART—Metabolism—ENO2—sarcoma	1.62e-06	0.00949	CbGpPWpGaD
Pemetrexed—GART—Metabolism—HBA1—sarcoma	1.61e-06	0.00943	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—MDM2—sarcoma	1.49e-06	0.00874	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	1.49e-06	0.00872	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—MYC—sarcoma	1.48e-06	0.00871	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—STAG1—sarcoma	1.47e-06	0.00861	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—STAG1—sarcoma	1.43e-06	0.0084	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PLCG1—sarcoma	1.37e-06	0.00805	CbGpPWpGaD
Pemetrexed—DHFR—E2F transcription factor network—MYC—sarcoma	1.37e-06	0.00805	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TLE1—sarcoma	1.33e-06	0.00783	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	1.3e-06	0.00763	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—CCND1—sarcoma	1.3e-06	0.00761	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—STAG1—sarcoma	1.28e-06	0.00751	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—NPM1—sarcoma	1.26e-06	0.00738	CbGpPWpGaD
Pemetrexed—DHFR—Folate Metabolism—TP53—sarcoma	1.22e-06	0.00717	CbGpPWpGaD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—TP53—sarcoma	1.22e-06	0.00715	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NPM1—sarcoma	1.2e-06	0.00707	CbGpPWpGaD
Pemetrexed—TYMS—E2F transcription factor network—MYC—sarcoma	1.2e-06	0.00703	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—MYC—sarcoma	1.19e-06	0.007	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—ENO2—sarcoma	1.12e-06	0.00658	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—HBA1—sarcoma	1.11e-06	0.00654	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—NPM1—sarcoma	1.1e-06	0.00644	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CCND1—sarcoma	1.05e-06	0.00614	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—ENO2—sarcoma	1.04e-06	0.00612	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—MYC—sarcoma	1.04e-06	0.00611	CbGpPWpGaD
Pemetrexed—DHFR—G1/S Transition—MYC—sarcoma	9.95e-07	0.00584	CbGpPWpGaD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—TP53—sarcoma	9.79e-07	0.00575	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	9.59e-07	0.00563	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PLCG1—sarcoma	9.51e-07	0.00558	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—CREB1—sarcoma	9.2e-07	0.00541	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CCND1—sarcoma	9.12e-07	0.00536	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PLCG1—sarcoma	8.84e-07	0.00519	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—ENO2—sarcoma	8.73e-07	0.00513	CbGpPWpGaD
Pemetrexed—TYMS—G1/S Transition—MYC—sarcoma	8.68e-07	0.0051	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—HBA1—sarcoma	8.67e-07	0.00509	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—TP53—sarcoma	8.54e-07	0.00501	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CXCR4—sarcoma	8.5e-07	0.00499	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—MYC—sarcoma	8.38e-07	0.00492	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	7.93e-07	0.00466	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PLCG1—sarcoma	7.41e-07	0.00435	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—MYC—sarcoma	7.32e-07	0.0043	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TLE1—sarcoma	7.15e-07	0.0042	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	6.91e-07	0.00406	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	6.9e-07	0.00405	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	6.84e-07	0.00402	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—JUN—sarcoma	6.62e-07	0.00389	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NPM1—sarcoma	6.45e-07	0.00379	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—FOXO1—sarcoma	6.27e-07	0.00368	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PDGFRB—sarcoma	6.26e-07	0.00368	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	6.19e-07	0.00363	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PDGFRA—sarcoma	6.17e-07	0.00362	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	6.02e-07	0.00354	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ENO2—sarcoma	5.82e-07	0.00342	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—HBA1—sarcoma	5.79e-07	0.0034	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ENO2—sarcoma	5.59e-07	0.00328	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	5.54e-07	0.00326	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	5.42e-07	0.00318	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	5.12e-07	0.00301	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PLCG1—sarcoma	4.94e-07	0.0029	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—KIT—sarcoma	4.78e-07	0.00281	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PLCG1—sarcoma	4.74e-07	0.00278	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ENO2—sarcoma	4.68e-07	0.00275	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—HBA1—sarcoma	4.65e-07	0.00273	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CXCR4—sarcoma	4.56e-07	0.00268	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	4.55e-07	0.00267	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CREB1—sarcoma	4.55e-07	0.00267	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—TP53—sarcoma	4.37e-07	0.00257	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ENO2—sarcoma	4.08e-07	0.0024	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—HBA1—sarcoma	4.06e-07	0.00238	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PLCG1—sarcoma	3.97e-07	0.00233	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MDM2—sarcoma	3.94e-07	0.00231	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND1—sarcoma	3.83e-07	0.00225	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MDM2—sarcoma	3.77e-07	0.00221	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PLCG1—sarcoma	3.46e-07	0.00203	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MDM2—sarcoma	3.43e-07	0.00202	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND1—sarcoma	3.43e-07	0.00201	CbGpPWpGaD
Pemetrexed—DHFR—Disease—FOXO1—sarcoma	3.36e-07	0.00198	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PDGFRB—sarcoma	3.36e-07	0.00197	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND1—sarcoma	3.35e-07	0.00196	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PDGFRA—sarcoma	3.31e-07	0.00194	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CTNNB1—sarcoma	3.25e-07	0.00191	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MYC—sarcoma	3.07e-07	0.00181	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND1—sarcoma	2.99e-07	0.00176	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—SRC—sarcoma	2.94e-07	0.00172	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NRAS—sarcoma	2.82e-07	0.00166	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MYC—sarcoma	2.75e-07	0.00161	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MYC—sarcoma	2.68e-07	0.00158	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MYC—sarcoma	2.63e-07	0.00154	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EGFR—sarcoma	2.57e-07	0.00151	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KIT—sarcoma	2.56e-07	0.00151	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CREB1—sarcoma	2.44e-07	0.00143	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—KRAS—sarcoma	2.43e-07	0.00143	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MYC—sarcoma	2.4e-07	0.00141	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TP53—sarcoma	2.26e-07	0.00133	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—HRAS—sarcoma	2.07e-07	0.00121	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MDM2—sarcoma	2.02e-07	0.00119	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TP53—sarcoma	1.97e-07	0.00116	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CTNNB1—sarcoma	1.74e-07	0.00102	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SRC—sarcoma	1.57e-07	0.000924	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NRAS—sarcoma	1.51e-07	0.000889	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MYC—sarcoma	1.41e-07	0.000828	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EGFR—sarcoma	1.38e-07	0.00081	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KRAS—sarcoma	1.3e-07	0.000765	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HRAS—sarcoma	1.11e-07	0.000651	CbGpPWpGaD
